Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers June 10, 2021

Published By :
June 10, 2021
email icon in blackFacebook icon in blacktwitter icon in blackLinkedIn icon in black
gradient colors in orange, pink and purple

Recent News & Insights

Enable Injections Expands Strategic Partnership with Roche

Featured News
·
May 7, 2024

Genetesis Selected for Spoke Membership in ARPA-H Investor Catalyst Hub

Featured News
·
May 1, 2024

Abre Secures $24 Million Series A Investment to Fuel Growth and Student Impact in K-12 Education

Featured News
·
April 11, 2024
More News And Insights
Subscribe TO our newsletter

Stay Up To Date With Our News & Insights

Stay informed with current news about our portfolio companies, events and industry insights.
email icon in gradient orange, pink and purple colors
You are subscribed to our newsletters
Oops! Something went wrong while submitting the form.
CincyTech is a venture capital firm that invests in innovative founders tackling the world's complex challenges. Our experienced team is fluent in the language of founders, researchers, and inventors working with deep domain expertise and market foresight. We partner early to help transform ideas into world-class companies.
2900 Reading Rd. Ste. 410 Cincinnati, OH 45206
Contact CincyTech
Twitter icon in white
Cincytech logo
HomeApproachPortfolioTeamCommunityNews & InsightsPitch Us
© 2023 Copyright - CincyTech
CareersUniversity ProgramsDisclosures
Made by 5Four Digital®